Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

*Kate F. Whitecross,¹ *Amber E. Alsop,¹ Leonie A. Cluse,¹ Adrian Wiegmans,¹ Kellie-Marie Banks,¹ Claudia Coomans,¹ Melissa J. Peart,² Andrea Newbold,¹ Ralph K. Lindemann,³ and Ricky W. Johnstone¹,⁴

¹Cancer Immunology Program, The Peter MacCallum Cancer Centre, Trescowthick Research Laboratories, East Melbourne, Australia; ²Department of Biological Sciences, Columbia University, New York, NY; ³Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany; and ⁴University of Melbourne, Melbourne, Australia

The apoptotic and therapeutic activities of the histone deacetylase inhibitor (HDACi) vorinostat are blocked by overexpression of Bcl-2 or Bcl-XL. Herein, we used the small molecule inhibitor ABT-737 to restore sensitivity of Eµ-myc lymphomas overexpressing Bcl-2 or Bcl-XL to vorinostat and valproic acid (VPA). Combining low-dose ABT-737 with vorinostat or VPA resulted in synergistic apoptosis of these cells. ABT-737 was ineffective against Eµ-myc/Mcl-1 and Eµ-myc/A1 cells either as a single agent or in combination with HDACi. However, in contrast to the reported binding specificity data, Eµ-myc/Bcl-w lymphomas were insensitive to ABT-737 used alone or in combination with HDACi, indicating that the regulatory activity of ABT-737 is restricted to Bcl-2 and Bcl-XL. Eµ-myc lymphomas that expressed Bcl-2 throughout the tumorigenesis process were especially sensitive to ABT-737, while those forced to overexpress Mcl-1 were not. This supports the notion that tumor cells “addicted” to ABT-737 target proteins (ie, Bcl-2 or Bcl-XL) are likely to be the most sensitive target cell population. Our studies provide important preclinical data on the binding specificity of ABT-737 and its usefulness against primary hematologic malignancies when used as a single agent and in combination with HDACi. (Blood. 2009;113:1982-1991)

Introduction

Histone deacetylase inhibitors (HDACis) are a new class of chemotherapeutic drugs that inhibit the enzymatic activity of HDACs, resulting in chromatin remodeling and altered gene transcription.¹ These agents can induce tumor cell apoptosis, inhibit cell proliferation by blocking progression through the G1 or G2/M phases of the cell cycle, induce cellular differentiation, suppress angiogenesis, and modulate antitumor immunity.¹ Using genetic mouse models of cancer, we and others have recently demonstrated a direct link between HDACi-mediated apoptosis and therapeutic efficacy,²,³ indicating that direct tumor cell killing by these agents plays an important role in mediating antitumor responses in vivo. We genetically manipulated primary Eµ-myc lymphoma cells to functionally inactivate either extrinsic apoptotic pathway signaling, by overexpression of the viral serpin CrmA or gene knockout of TRAIL, or the intrinsic apoptotic pathway, by overexpression of the prosurvival Bcl-2 proteins Bcl-2 or Bcl-XL, and tested for the ability of the HDACi vorinostat to kill these cells and mediate a therapeutic response.³ We found that disruption of death receptor signaling had no effect on the apoptotic and therapeutic activity of vorinostat. However, inhibition of mitochondrial membrane permeabilization and subsequent suppression of the intrinsic apoptotic pathway by overexpressed Bcl-2 or Bcl-XL completely inhibited vorinostat-induced apoptosis and abolished any therapeutic benefit. These data indicate that the clinical use of vorinostat and other HDACi as monotherapies may be limited to those tumors that do not overexpress prosurvival Bcl-2 proteins.

However, we hypothesize that agents that inhibit the expression and/or function of prosurvival Bcl-2 family proteins may sensitize cells to HDACi-mediated apoptosis, providing a rationale for the clinical development of such combination approaches.

The Bcl-2 family consists of 3 major subgroups: (1) Multi-domain prosurvival proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1) that share 4 Bcl-2 homology (BH) domains; (2) BH3-only proapoptotic proteins (Bid, Bim, Bik, Bmf, Noxa, Puma, Hrk, Bad) that contain only a 9- to 16-amino-acid region of BH3; (3) multidomain proapoptotic proteins (Bax, Bak, Bok) that share BH domains 1, 2, and 3.⁷ BH3-only proteins are “activated” by exogenous signals such as growth factor deprivation, irradiation, and chemotherapeutic drugs. These proteins can trigger the intrinsic apoptotic pathway by binding prosurvival Bcl-2 proteins, thereby relieving the inhibitory effect on Bax and Bak⁵,⁶ and/or by directly binding to and activating Bax and Bak.⁷,⁸

ABT-737 is a BH3-only mimetic compound developed to specifically inhibit the activity of prosurvival Bcl-2 family proteins.⁹ The binding specificity of ABT-737 was determined using competitive fluorescence polarization assays and recombinant proteins demonstrating that ABT-737 had “Bad-like” activity in that it preferentially bound Bcl-2, Bcl-XL, and Bcl-w, with inhibitory constants (Ki) less than or equal to 1 nM. In contrast, the affinity of ABT-737 for Mcl-1 and A1 was far lower (Ki > 1 μM).⁹ Similar biochemical assays using recombinant full-length or truncated prosurvival Bcl-2 proteins confirmed that ABT-737 had
Eμ-myc lymphomas, cell culture, and reagents

Eμ-myc lymphomas were isolated from Eμ-myc transgenic mice by harvesting enlarged brachioaxial and mesenteric lymph nodes. A cell suspension was prepared, filtered through nylon mesh, and then stored in liquid N2. Eμ-myc/Bcl-2, Eμ-myc/Bcl-XL, Eμ-myc/Bcl-w, Eμ-myc/Mcl-1, and Eμ-myc/A1 lymphomas were engineered by retroviral transduction of freshly isolated lymphoma cells. For this purpose, retrovirus-containing supernatant was produced by transfecting packaging cells with murine stem cell virus-internal ribosome entry site–green fluorescent protein plasmid (MSCV-IRE-S-GFP), MSCV-IRE-S-GFP/Bcl-2, MSCV-IRE-S-GFP/Bcl-XL, MSCV-IRE-S-GFP/Flag-Bcl-w, MSCV-IRE-S-GFP/Bcl-w, MSCV-IRE-S-GFP/Mcl-1, MSCV-IRE-S-GFP/Mcl-1, and MSCV-IRE-S-GFP/Flag-Mcl-1 and analysis of tumor latency was performed as described.21

Vorinostat was kindly provided by Merck (Whitehouse Station, NJ), ABT-737 was kindly provided by Abbott Laboratories (Abbott Park, IL), and VPA was purchased from Sigma-Aldrich (St Louis, MO). For in vitro experiments, stock solutions of vorinostat and ABT-737 (10 mM and 50 mM, respectively) were prepared by dissolution in dimethyl sulfoxide (DMSO). For in vivo experiments, vorinostat was dissolved in DMSO to give a stock of 100 mg/mL, while ABT-737 was dissolved in DMSO at 500 mg/mL and then diluted 1:25 in a solution of 30% 1,2 propanediol, 5% Tween 80, and 65% D5W (5% dextrose, pH 1.0). This 10 mg/mL ABT-737 solution was sonicated, and the pH adjusted to 4.2 to 4.3. All stock solutions were stored at −20°C.

Western blot

Western blot assays using whole cell lysates were performed as previously described1 using primary antibodies against mouse Bcl-2 (BD Biosciences, San Jose, CA), mouse Bcl-XL (Santa Cruz Biotechnology, Santa Cruz, CA), Flag epitope (Sigma-Aldrich), Bcl-w (Millipore, Billerica, MA), Mcl-1 (Rockland, Gilbertsville, PA), α-tubulin and β-actin (both Sigma-Aldrich).

In vitro cell-death analysis

Eμ-myc lymphoma cells (5 × 10⁶ cells/mL) were incubated in the presence of the indicated compounds for 20 hours in 1 mL cell culture media in 24-well plates (Greiner Bio-One). Viability of cells was measured by propidium iodide (PI) uptake, cell-cycle analysis, or tetramethylrhodamine ethyl ester (TMRE) staining as described.3 Clonogenic assays were performed as described.22

In vivo assays

C57BL/6 mice were injected intravenously with 1 to 6 × 10⁵ Eμ-myc lymphoma cells, and mice with established tumors were injected with 25, 75, or 100 mg/kg ABT-737, 200 mg/kg vorinostat, or a combination of the 2 agents by intraperitoneal injection. Control mice were injected intraperitoneally with DMSO or the vehicle for ABT-737. At various time points, peripheral blood was collected into tubes containing 10 mM EDTA.
(ethylene diaminetetraacetic acid), diluted in phosphate-buffered saline (PBS), and white blood cell (WBC) and platelet numbers were calculated (Advia 120 Hematology System; Siemens Healthcare Diagnostics, Deerfield, IL). At each time point in repetitive dosing experiments, mean WBC counts were compared using a 2-tailed Mann-Whitney t test. Approval was obtained from the Peter MacCallum Cancer Centre Animal Experimentation institutional review board for these studies.

Results

Prosurvival Bcl-2 proteins confer resistance to HDACi-induced apoptosis

We have previously demonstrated that overexpression of Bcl-2 or Bcl-XL in established human tumor lines and primary \( E\mu\)-myc lymphomas confers resistance to HDACi-induced apoptosis in vitro and suppresses the therapeutic activity of vorinostat in vivo. To determine whether other prosurvival Bcl-2 proteins could also suppress the apoptotic activities of HDACi, we developed populations of tumor cells differing only in their expression of prosurvival Bcl-2 family proteins by retroviral transduction of lymphoma cells isolated from \( E\mu\)-myc transgenic mice. A control population was generated by transduction of cells with empty retroviral vector.

After confirming the overexpression of prosurvival Bcl-2-family proteins in each test population of tumor cells by western blot (Figure S1A, available on the Blood website; see the Supplementary Materials link at the top of the online article), control and test tumor cells were exposed in vitro to varying concentrations of the structurally different HDACis vorinostat and VPA, for 20 to 24 hours and then assessed for (1) loss of plasma membrane integrity by PI uptake; (2) loss of mitochondrial outer membrane potential (MOMP) by a decrease in TMRE staining; and (3) DNA fragmentation by cell-cycle analysis. Control tumor cells were sensitive to vorinostat and VPA in a concentration-dependent manner (Figures 1A,B, S1C). In contrast, test tumor cells overexpressing any one of the prosurvival Bcl-2 proteins were relatively resistant to vorinostat and VPA. Similar results were observed using a second, independently derived, set of test and control tumor cells generated from another \( E\mu\)-myc transgenic mouse (Figure S4B). These data were further confirmed after analysis of a third set of matched control and test lymphomas overexpressing Bcl-2 or Bcl-w (Figure S4B) that demonstrated again that ABT-737 was ineffective against lymphomas that overexpressed Bcl-w.

Our findings that ABT-737 had specificity for Bcl-2 and Bcl-XL, but not Bcl-w, were counter to the biochemical data previously published. We first ensured that the sequence of the DNA fragment used to generate the retroviral vector that resulted in overexpression of Bcl-w in our tumor cells was identical to the published sequence of murine Bcl-w, which is translated to an amino acid sequence that differs from human Bcl-w at only 2 residues (Figure S5A). Neither of these is located in the BH domains forming the BH3 binding groove of Bcl-w (Figure S5B), indicating that it is unlikely that these 2 amino acid changes would confer functional differences between the human and mouse Bcl-w proteins. We next tested whether the FLAG epitope positioned at the amino-terminus of Bcl-w that we expressed in our lymphoma cells might affect the activity of ABT-737. The presence of the FLAG epitope did not appear to affect the ability of Bcl-w to confer resistance to the HDACi vorinostat and VPA (Figure 1), or more conventional agents, such as etoposide (data not shown). However, to rule out the possibility that the additional amino acids had affected the binding affinity of ABT-737 for Bcl-w, we generated another set of Bcl-w–overexpressing test tumor cells using a retroviral vector that resulted in expression of a nontagged, wild-type Bcl-w protein. When tested with varying concentrations of ABT-737 or its less potent enantiomer for 20 to 24 hours, these cells had the same pattern of insensitivity to ABT-737 as the tumor cells overexpressing FLAG-tagged Bcl-w protein (Figure S6A). As overexpression of Mcl-1 may confer resistance to ABT-737 in cells that express Bcl-2, we checked, by western blotting, the expression level of Mcl-1 in control tumor cells and test tumor cells overexpressing both nontagged or FLAG-tagged Bcl-w, or Bcl-2. All 4 lymphomas showed comparable levels of endogenous Mcl-1 expression (Figure S6B). Finally, we produced \( E\mu\)-myc lymphomas overexpressing human Bcl-w and demonstrated that these cells were also refractory to apoptosis mediated by ABT-737 (Figure S6C).

ABT-737 induces apoptosis in tumor cells overexpressing Bcl-2 or Bcl-XL, but is ineffective as an inhibitor of Bcl-w, Mcl-1, or A1

To test our hypothesis, we decided to coinubate our test and control tumor cells with the HDACis vorinostat or VPA and the small molecule ABT-737, which reportedly has a high affinity for Bcl-2, Bcl-XL, and Bcl-w, but not for Mcl-1 or A1. First, however, we determined the sensitivity of tumor cells overexpressing Bcl-2 family proteins to ABT-737 alone. Control cells and tumors overexpressing Bcl-2 were exposed in vitro to varying concentrations of ABT-737 or its less potent enantiomer (ABT-737e) for 20 to 24 hours and then assessed for cell viability as before. Tumor cells overexpressing Bcl-2 were sensitive to as little as 0.1 \( \mu \)M ABT-737 as assessed by increased uptake of PI and loss of MOMP (Figure 2A,B), and an increase in DNA fragmentation (see Figure S6C). At 1 \( \mu \)M ABT-737, more than 60% of these tumor cells had lost MOMP and plasma membrane integrity (Figure 2B). In contrast, control lymphomas were not sensitive to apoptosis mediated by ABT-737 until doses as high as 10 and 100 \( \mu \)M were used, even though these cells showed a higher basal percentage of apoptotic cells when grown in the absence of any ABT-737 (Figure 2A). Similar results were obtained using 2 additional sets of matched control and Bcl-2–overexpressing lymphomas (Figure S3).

Tumor cells overexpressing Bcl-XL were also sensitive to apoptosis induced by ABT-737 and were relatively resistant to ABT-737e (Figure 2B). In contrast, tumor cells overexpressing Mcl-1 or A1 were resistant to both ABT-737 and ABT-737e except at the highest dose used (100 \( \mu \)M; Figure 2B). Unexpectedly, tumor cells overexpressing Bcl-w had a similar pattern of insensitivity to ABT-737 as tumor cells overexpressing Mcl-1 or A1 (Figure 2B). As before, similar results were observed using a second, independently derived, set of test and control tumor cells generated from another \( E\mu\)-myc transgenic mouse (Figure S4A). These data were further confirmed after analysis of a third set of matched control and test lymphomas overexpressing Bcl-2 or Bcl-w (Figure S4B) that demonstrated again that ABT-737 was ineffective against lymphomas that overexpressed Bcl-w.
To ensure that the insensitivity of tumor cells overexpressing Bcl-w, Mcl-1, or A1 to ABT-737 was not merely due to a delay in ABT-737-induced apoptosis, we performed colony assays on our set of control and test tumor cells. Tumor cells were exposed to 1 μM of ABT-737 for 22 to 24 hours and seeded into agar, and the number of colonies arising counted 6 days later. Consistent with our dose response assays (Figure 2), the number of colonies (<40% relative to untreated cells) arising from ABT-737–treated tumor cells overexpressing Bcl-2 and Bcl-X<sub>l</sub> was significantly decreased in comparison to ABT-737–treated control cells, or tumor cells overexpressing Mcl-1, A1, and Bcl-w (>90% relative to untreated cells; Figure 3).

In summary, these results demonstrate that ABT-737 is effective at inducing apoptosis in tumor cells overexpressing Bcl-2 or Bcl-X<sub>l</sub>, but is ineffective as an inhibitor of Bcl-w, Mcl-1, or A1.

**HDACi and ABT-737 induce synergistic apoptosis in tumor cells overexpressing Bcl-2 or Bcl-X<sub>l</sub> lymphomas**

Our results thus far indicated that apoptosis mediated by vorinostat and VPA was inhibited by all prosurvival Bcl-2 family proteins and ABT-737 could specifically inhibit the activity of Bcl-2 and Bcl-X<sub>l</sub> but does not affect Bcl-w, Mcl-1, and A1. We therefore proposed that a combination of HDACi and ABT-737 would be effective in Eμ-myc/Bcl-2, Eμ-myc/ Bcl-X<sub>l</sub> lymphomas, and we wished to determine whether these compounds could induce synergistic apoptosis in these cells. ABT-737–sensitive tumor cells (ie, those overexpressing Bcl-2 or Bcl-X<sub>l</sub>) were exposed in vitro for 20 to 24 hours to varying concentrations of vorinostat or VPA in the presence 0.5 μM ABT-737 or ABT-737e. Tumor cells overexpressing Bcl-w, Mcl-1, and A1 were treated similarly, except 1 μM ABT-737 or
ABT-737e was used. As before, tumor cells overexpressing any of the prosurvival proteins were relatively insensitive to 0.5 to 5 μM vorinostat, 0.1 to 1.0 mM VPA, and 0.5 or 1 μM ABT-737 when used alone (Figures 4, S7A). However, when vorinostat and ABT-737 (Figure 4) or VPA and ABT-737 (Figure S7A) were combined, tumor cells overexpressing Bcl-2 or Bcl-XL showed a decrease in viability as assessed by increased uptake of PI and loss of MOMP, and an increase in DNA fragmentation (sub G1 cells; Figures 4, S7B). For tumor cells overexpressing Bcl-2 in particular, the response to the combination was comparable to that of control cells treated only with vorinostat or VPA (Figures 4, S7B). As expected from our single-agent tests (Figures 1-3), tumor cells overexpressing Mcl-1, A1, or Bcl-w were resistant to 0.5 to 5 μM vorinostat and 0.1 to 1.0 mM VPA, despite the presence of 1 μM ABT-737 (Figures 4, S7).
These results, therefore, indicate that HDACi and ABT-737 can function synergistically to kill tumor cells overexpressing Bcl-2 or Bcl-XL. Moreover, we have confirmed our previous observations that ABT-737 specifically inhibits only Bcl-2 or Bcl-XL and has no effect on Mcl-1, A1, or surprisingly, Bcl-w.

**ABT-737 is effective in noncycling tumor cells that overexpress Bcl-2**

We demonstrated that overexpression of Bcl-2 or Bcl-XL in established Eμ-myc lymphomas led to increased sensitivity to ABT-737 compared with that observed using parental Eμ-myc cells. This model might represent a situation where increased expression of prosurvival Bcl-2 proteins in established tumors occurs after additional cell stress (ie, after exposure to chemotherapeutic drugs) or due to selection of a small pool (or clone) of cells that overexpress such apoptosis inhibitory proteins in response to apoptotic stimuli. We were interested to determine whether Eμ-myc lymphoma cells that develop in the presence of overexpressed Bcl-2 may be hypersensitive to ABT-737 as these cells may be more “addicted” to the presence of functional Bcl-2. To assess this,
significantly more sensitive to ABT-737 compared with FLR lymphomas overexpressing Mcl-1 (Figure 5C). Of note, FLR lymphomas overexpressing Bcl-2 were greater than 10-fold more sensitive to ABT-737 than were lymphomas in which Bcl-2 was overexpressed subsequent to the tumorigenic process (Figures 2B, 5C). Moreover, we noted that FLR lymphomas overexpressing Bcl-2 grown ex vivo did not proliferate when cultured for up to 3 days (data not shown) and appeared to be arrested in the G1 phase of the cell cycle (Figure 5D). This demonstrated that ABT-737 effectively killed Bcl-2-overexpressing tumor cells even if the cells were quiescent.

**ABT-737 selectively kills lymphomas overexpressing Bcl-2 in vivo and synergizes with vorinostat in mice bearing FLR lymphomas overexpressing Bcl-2**

Our in vitro data demonstrated that ABT-737 selectively killed tumor cells overexpressing Bcl-2 or Bcl-X<sub>L</sub> and at lower doses could sensitize these cells to vorinostat-induced apoptosis. To determine whether these effects could be recapitulated in vivo, we treated mice bearing established FLR lymphomas overexpressing Bcl-2, Bcl-w, or Mcl-1 with ABT-737. As demonstrated in Figure 6A, treatment of mice bearing FLR lymphomas overexpressing Bcl-2 with a single dose of 75 or 100 mg/kg ABT-737 resulted in a decrease in tumor burden 12 hours after administration of the compound. At the 100 mg/kg dose, WBC levels were restored to physiologic levels (Figure 6A). In contrast, treatment of FLR lymphomas overexpressing Bcl-w or Mcl-1 had no significant effect on WBC numbers (Figure 6A). The activity of ABT-737 at the doses used in these experiments was demonstrated by the dramatic reduction in platelet numbers in the treated tumor-bearing mice (Figure 6A), which is consistent with previous studies demonstrating that ABT-737 directly induces apoptosis of platelets in vivo. To further demonstrate the in vivo effects of ABT-737 used at a relatively high dose as a single agent, mice bearing FLR lymphomas overexpressing Bcl-2 or Bcl-w were treated daily for 1 week with 100 mg/kg ABT-737. As shown in Figure 6Bi, the tumor burden in mice bearing FLR lymphomas overexpressing Bcl-2 was significantly reduced after treatment with ABT-737 for 7 days. In contrast, ABT-737 had no effect on the WBC counts in mice with established FLR lymphomas overexpressing Bcl-w (Figure 6Bi). Extended daily treatment of mice bearing FLR lymphomas overexpressing Bcl-2 with ABT-737 resulted in a sustained suppression of tumor load, however after removal of the agent the WBC counts elevated and the mice became leukemic (Figure 6Bi).

To demonstrate in vivo synergy using the combination of ABT737 and vorinostat, mice bearing FLR lymphomas overexpressing Bcl-2 were treated vorinostat or ABT-737 alone at doses that had little or no effect on tumor load (Figure 6Ci). However, a combination of vorinostat and ABT-737 at these doses resulted in a significant decrease in WBC numbers. Importantly, and in contrast to the data shown in Figure 6A, these doses of vorinostat or ABT-737, used alone or in combination had little or no effect on the platelet counts in the treated mice (Figure 6Ci). These data demonstrate that ABT-737 and vorinostat can synergistically kill Bcl-2-overexpressing tumor cells in vivo at doses that cause no demonstrable side effects.

**Discussion**

Recent evidence using preclinical mouse models of cancer suggests that the therapeutic effects of HDACi are dependent on their ability to mediate apoptosis. We have shown that the HDACi vorinostat induced tumor cell apoptosis via activation of the intrinsic apoptotic pathway, and overexpression of Bcl-2 or Bcl-X<sub>L</sub> inhibited the apoptotic and therapeutic activities of the compound. We therefore hypothesized that a combination of vorinostat and an inhibitor of Bcl-2 and/or Bcl-X<sub>L</sub> would be effective in killing those tumors that are resistant to vorinostat due to overexpression of these prosurvival proteins. Herein, we used ABT-737, a small molecule inhibitor of prosurvival Bcl-2 proteins with putative specificity for Bcl-2, Bcl-X<sub>L</sub>, and Bcl-w, to test our hypothesis.

Using established primary Eμ-myc lymphoma cells induced to overexpress Bcl-2, Bcl-X<sub>L</sub>, Bcl-w, Mcl-1, or A1, we found all 5 prosurvival Bcl-2 proteins could confer resistance to 2 structurally different HDACis, vorinostat and VPA. Enforced expression of Bcl-2 and Bcl-X<sub>L</sub>, but not Bcl-w, Mcl-1, or A1 sensitized Eμ-myc
lymphoma cells to death induced by ABT-737 used as a single agent. Accordingly, ABT-737 could synergize with vorinostat or VPA in vitro to kill tumors overexpressing Bcl-2 and Bcl-X<sub>L</sub>, but not those lymphoma cells overexpressing Bcl-w, Mcl-1, or A1. Moreover, we found that Eq-myc lymphomas that develop in the presence of overexpressed Bcl-2 were hypersensitive to apoptosis mediated by ABT-737, despite being arrested in G<sub>1</sub>. Importantly, we demonstrated that our in vitro data could be recapitulated in mice bearing lymphoma cells overexpressing Bcl-2, Mcl-1, or Bcl-w. Tumor burden was dramatically reduced in mice with FLR Eq-myc/Bcl-2 cells using a single relatively high dose of ABT-737 that caused a concomitant reduction in platelet numbers in the peripheral blood. In contrast, no such therapeutic effect was seen in ABT-737-treated mice bearing tumors overexpressing Mcl-1 or Bcl-w. Finally, we demonstrated that ABT-737 and vorinostat could cooperate in vivo to reduce the tumor burden of mice bearing lymphoma cells overexpressing Bcl-2, at doses that did not cause a demonstrable decrease in platelet numbers.

Chemoresistance that arises after initial rounds of therapy is frequently associated with overexpression of prosurvival Bcl-2 family proteins. Such “acquired resistance” may result from genetic alterations precipitated by exposure to genotoxic agents and/or from drug-induced selection of resistant clones. Our data indicate that regardless of the mechanism responsible, tumors with acquired addiction to Bcl-2 or Bcl-X<sub>L</sub> that, therefore, develop sustained resistance to conventional chemotherapeutic drugs and agents such as HDACis, may be prime targets for compounds like ABT-737. Such agents may, therefore, be particularly useful as second-line therapies after more conventional first-line treatment with cytotoxic agents. Undoubtedly, not all tumor cells overexpressing Bcl-2 or Bcl-X<sub>L</sub> will be sensitive to ABT-737 or similar compounds. For example, loss of expression or function of certain BH3-only proteins, or key sensitizers of “oncogenic stress” such as p53, that function upstream of the Bcl-2 family proteins could suppress the intrinsic pathway apoptotic signal. Accordingly, these cells would be rendered less sensitive to ABT-737 as a single agent as these cells may not be “primed” to die once the prosurvival signal provided by Bcl-2 or Bcl-X<sub>L</sub> is released. In these circumstances, the combination of ABT-737 and an HDACi could be effective since HDACis have been shown to rapidly increase the expression or otherwise activate multiple BH3-only proteins including Bmf, Bim, Bid, Puma, Noxa, and Bad, and can function in the absence of wild-type p53. Indeed, we have recent data indicating that pretreatment of Eq-myc/Bcl-2 and Eq-myc/Bcl-X<sub>L</sub> cells with vorinostat for 12 to 16 hours at nonapoptotic doses sufficiently “primes” cells for rapid (4-8 hours) and robust (> 60% apoptosis) cell death using low concentrations (< 0.5 μM) of ABT-737 (data not shown). Furthermore, we found that a combination of vorinostat and ABT-737 at doses that alone had no effect on tumor load in vivo, effectively reduced the number of FLR lymphoma cells overexpressing Bcl-2 present in the peripheral blood. These preclinical proof-of-principal experiments show that the combination of HDACi and ABT-737 may be a therapeutically attractive approach.

For personal use only.on April 19, 2017. By guest
Our data also demonstrate that ABT-737 may have a more selective target specificity profile for Bcl-2 family proteins than originally thought. The affinity of ABT-737 for Bcl-2, Bcl-XL, and Bcl-w had been previously determined using competitive binding assays that used recombinant proteins and peptides representing BH3-only domains. It is possible that the biochemical binding assays used to define the target specificity of ABT-737 may not have reflected the physiologic situation. Indeed, the hydrophobic groove within Bcl-w that docks with the BH3 domain of BH3-only proteins has been shown to be occupied by an α-helix located within its own C-terminal tail in vivo. This feature serves to regulate access to BH3 domains to the hydrophobic groove of Bcl-w, and this could similarly prevent access to small molecule BH3 mimetics such as ABT-737. Indeed, consistent with our own data, it was recently shown that elevated expression of Bcl-w mRNA was a feature of primary acute lymphoblastic leukemias resistant to ABT-263, a structural analog of ABT-737.

Eq-myc lymphomas that developed in the presence of overexpressed Bcl-2 were highly “addicted” to the prosurvival protein, as these cells were at least 10 times more sensitive to ABT-737 than were established lymphomas that had enforced expression of Bcl-2 after cellular transformation. Accordingly, diseases such as follicular lymphoma, which develops as a result of deregulated expression of Bcl-2 caused by a t(14;18) chromosomal translocation, will be prime candidates for single agent therapy with ABT-737. Our ex vivo studies using FLR lymphomas overexpressing Bcl-2 provided a final important piece of information to our study, in that these cells did not proliferate in culture yet were highly sensitive to ABT-737. This may be important in the context of the utilization of ABT-737 to treat hematologic malignancies such as chronic lymphocytic leukemia that often overexpress Bcl-2 but have slow rates of proliferation and solid tumors that often contain a mix of highly proliferative and quiescent tumor cells.

References

8. Letti A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apopto-
9. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces re-
nisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leuke-
-
mcl-1-helix located within its own C-terminal tail in vivo. This feature serves to regulate access to BH3 domains to the hydrophobic groove of Bcl-w, and this could similarly prevent access to small molecule BH3 mimetics such as ABT-737. Indeed, consistent with our own data, it was recently shown that elevated expression of Bcl-w mRNA was a feature of primary acute lymphoblastic leukemias resistant to ABT-263, a structural analog of ABT-737.

Acknowledgments

We thank David Huang, Andreas Strasser, Clare Scott, Jerry Adams, Suzanne Cory, and Alan Harris from the Walter and Eliza Hall Institute for helpful advice, Eu-myc mice, and cDNAs for Bcl-2, Bcl-XL, Bcl-w, Mcl-1, and A1. We thank Drs Saul Rosenberg, Steve Elmore, Alex Shoemaker, and Victoria Richon for helpful advice and providing reagents. Vorinostat was kindly provided by Merck, and ABT-737 was kindly provided by Abbott Laboratories.

R.W.J. is a Pfizer Australia Research Fellow and is supported by a NHMRC (Canberra, Australia) Program Grant 251608, the Cancer Council Victoria (Melbourne, Australia), the Leukemia Foundation of Australia (Box Hill, Australia), and the Bennelong Foundation (Melbourne, Australia).

Authorship

Contribution: K.F.W. performed research and analyzed data; A.E.A. performed research, analyzed data, and wrote the paper; L.A.C. performed research and contributed vital new reagents; A.W., K.-M.B., and C.C. performed research; M.J.P. contributed vital new reagents; A.N. and R.K.L. performed research and contributed vital new reagents; and R.W.J. analyzed data and wrote the paper.

Conflict-of-interest disclosure: R.W.J. receives a collaborative research grant from Merck for research involving vorinostat. The other authors declare no competing financial interests.

Correspondence: Ricky Johnstone, Cancer Immunology Program, The Peter MacCallum Cancer Centre, Trescowthick Research Laboratories, St Andrews Place, East Melbourne 3002 Victoria, Australia; e-mail: ricky.johnstone@petermac.org.

1990 WHITECROSS et al BLOOD, 26 FEBRUARY 2009 • VOLUME 113, NUMBER 9


Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

Kate F. Whitecross, Amber E. Alsop, Leonie A. Cluse, Adrian Wiegmans, Kellie-Marie Banks, Claudia Coomans, Melissa J. Peart, Andrea Newbold, Ralph K. Lindemann and Ricky W. Johnstone